Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
XENE's Cash-to-Debt is ranked higher than
70% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. XENE: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
XENE' s Cash-to-Debt Range Over the Past 10 Years
Min: 36.13  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.93
XENE's Equity-to-Asset is ranked higher than
92% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. XENE: 0.93 )
Ranked among companies with meaningful Equity-to-Asset only.
XENE' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.44  Med: 0.93 Max: 0.95
Current: 0.93
-1.44
0.95
Interest Coverage No Debt
XENE's Interest Coverage is ranked higher than
62% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. XENE: No Debt )
Ranked among companies with meaningful Interest Coverage only.
XENE' s Interest Coverage Range Over the Past 10 Years
Min: 151.75  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: 4.23
Beneish M-Score: -3.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -3496.71
XENE's Operating Margin % is ranked lower than
86% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. XENE: -3496.71 )
Ranked among companies with meaningful Operating Margin % only.
XENE' s Operating Margin % Range Over the Past 10 Years
Min: -3496.71  Med: -41.07 Max: 39.15
Current: -3496.71
-3496.71
39.15
Net Margin % -3489.63
XENE's Net Margin % is ranked lower than
87% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. XENE: -3489.63 )
Ranked among companies with meaningful Net Margin % only.
XENE' s Net Margin % Range Over the Past 10 Years
Min: -3489.63  Med: -65.59 Max: 45.89
Current: -3489.63
-3489.63
45.89
ROE % -48.75
XENE's ROE % is ranked lower than
55% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. XENE: -48.75 )
Ranked among companies with meaningful ROE % only.
XENE' s ROE % Range Over the Past 10 Years
Min: -48.75  Med: -30.18 Max: -23.54
Current: -48.75
-48.75
-23.54
ROA % -45.92
XENE's ROA % is ranked lower than
60% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. XENE: -45.92 )
Ranked among companies with meaningful ROA % only.
XENE' s ROA % Range Over the Past 10 Years
Min: -45.92  Med: -13.59 Max: 20.43
Current: -45.92
-45.92
20.43
ROC (Joel Greenblatt) % -1965.79
XENE's ROC (Joel Greenblatt) % is ranked lower than
70% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. XENE: -1965.79 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
XENE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1965.79  Med: -323.44 Max: 539.88
Current: -1965.79
-1965.79
539.88
3-Year Revenue Growth Rate -65.40
XENE's 3-Year Revenue Growth Rate is ranked lower than
87% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. XENE: -65.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
XENE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -65.4
Current: -65.4
GuruFocus has detected 4 Warning Signs with Xenon Pharmaceuticals Inc XENE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» XENE's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

XENE Guru Trades in Q3 2016

Jim Simons 96,200 sh (+98.35%)
Steven Cohen 358,531 sh (unchged)
Wilbur Ross 412,479 sh (-5.48%)
» More
Q4 2016

XENE Guru Trades in Q4 2016

Jim Simons 114,200 sh (+18.71%)
Wilbur Ross 400,677 sh (-2.86%)
Steven Cohen 310,179 sh (-13.49%)
» More
Q1 2017

XENE Guru Trades in Q1 2017

Jim Simons 217,090 sh (+90.10%)
Steven Cohen 310,179 sh (unchged)
Wilbur Ross 380,784 sh (-4.96%)
» More
Q2 2017

XENE Guru Trades in Q2 2017

Steven Cohen 310,179 sh (unchged)
Wilbur Ross 375,784 sh (-1.31%)
Jim Simons 130,300 sh (-39.98%)
» More
» Details

Insider Trades

Latest Guru Trades with XENE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Wilbur Ross 2017-06-30 Reduce -1.31%$3 - $4.25 $ 3.25-17%375,784
Wilbur Ross 2017-03-31 Reduce -4.96%0.03%$3.95 - $9.85 $ 3.25-59%380,784
Wilbur Ross 2016-12-31 Reduce -2.86%0.02%$7.5 - $8.55 $ 3.25-60%400,677
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 3741
Compare:TSE:4570, NAS:TCON, ASX:AHZ, NGM:MERT MTF A, XTER:WL6, XTAE:APOP, OTCPK:ANTB, WAR:PHR, LSE:SCLP, ASX:ANR, ROCO:4728, XKRX:000220, NAS:CAPR, NAS:PTI, NAS:MBRX, NAS:AZRX, NAS:KMPH, TSX:TRIL, XKRX:002720, NAS:LPTX » details
Traded in other countries:XP0.Germany,
Headquarter Location:Canada
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its products portfolio includes Glybera, TV-45070.

Xenon Pharmaceuticals Inc was incorporated in the Province of British Columbia on November 5, 1996. The Company is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company has built a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Its products portfolio includes Glybera, TV-45070 & among others. The Xenon logo, "Extreme Genetics" is the trademark for the Company. Its products and product candidates compete with various therapies and drugs companies.

Top Ranked Articles about Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical Trial
Xenon Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update
Xenon Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference
Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2017 Financial Results and Provide Corporate Update
Xenon Pharmaceuticals to Present at the 2017 Bloom Burton & Co. Healthcare Investor Conference
Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy
Xenon Pharmaceuticals Announces XEN801 Did Not Meet Efficacy Endpoints in Phase 2 Clinical Trial in Patients with Moderate to Severe Acne

Company to Hold Conference Call at 8:30 am ET Today

BURNABY, British Columbia, March 24, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today reported topline efficacy results from the double-blind, multi-center, vehicle-controlled, parallel-group study designed to evaluate the efficacy, safety, tolerability and systemic exposure of XEN801 for the treatment of moderate to severe facial acne.
XEN801 is a topical stearoyl Co-A desaturase-1, or SCD1 inhibitor, developed for the potential treatment of moderate to severe acne. Results from this trial showed that XEN801 did not demonstrate a statistically significant difference from vehicle placebo in its primary endpoint of the percent change in total (inflammatory and non-inflammatory) lesion count from baseline to week 12. The results also show that XEN801 did not demonstrate statistical significance relative to key secondary efficacy endpoints. XEN801 did demonstrate a favorable safety and tolerability profile, with no drug-related serious adverse events. Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, said, “Despite the good scientific and preclinical rationale to pursue SCD1 as a novel acne target, the topline clinical results do not support this hypothesis or the continued development of XEN801. While we are disappointed that XEN801 did not demonstrate efficacy in the treatment of acne, we have a broad, diversified pipeline of small molecule ion channel modulators based on targets with high human validation that we continue to advance.” Dr. Pimstone added, “We look forward to a number of important milestone events anticipated over the coming months, including a topline data read-out from the Phase 2b clinical trial of TV-45070 in post-herpetic neuralgia being conducted by our collaborator, Teva; the submission of an IND, or IND equivalent, for XEN901, our proprietary novel Nav1.6 inhibitor for the potential treatment of epilepsy, presently expected in the fourth quarter of this year; and advancement by our collaborator, Genentech, of its Nav1.7 pain program into Phase 2 expected this year.  In addition, our goal is to continue to expand our current proprietary pipeline of novel, ion channel modulators through both our internal research efforts and our ongoing assessment of promising external product opportunities.” Conference Call Information Xenon will host a conference call and live audio webcast today at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss the XEN801 Phase 2 clinical trial results. To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 94938286. The webcast will be broadcast live on the “Investors” section of Xenon's website at www.xenon-pharma.com and will be available for replay following the call for 30 days. About Xenon Pharmaceuticals Inc. Xenon is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that it intends to commercialize on its own and for larger market indications that the company intends to partner with global pharmaceutical companies. Xenon has built a core enabling discovery platform, referred to as Extreme Genetics, for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Xenon's Extreme Genetics platform has yielded the first approved gene therapy product in the European Union and a broad development pipeline and multiple pharmaceutical partnerships, including with Teva and Genentech. For more information, please visit www.xenon-pharma.com. Safe Harbor Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements include statements regarding our ability to achieve milestones in both our proprietary and partnered development programs,  the anticipated timing of IND submissions with regulatory agencies, the initiation of future clinical trials, the timing of and results from our and our collaborators’ ongoing clinical trials and pre-clinical development activities, the plans of our collaboration partners and their interactions with regulatory agencies, the potential efficacy, future development plans, regulatory success and commercial potential of our and our collaborators’ product candidates, the progress and potential of ongoing development programs and our plans to continue to expand our current proprietary pipeline through both internal research efforts and external opportunities. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical trials may not demonstrate safety and efficacy of any of our or our collaborators' product candidates; our Extreme Genetics discovery platform or ongoing collaborations may not yield additional product candidates; our efforts to expand our current pipeline may not be successful; any of our or our collaborators' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones pursuant to our collaboration agreements; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission and the securities commissions in British Columbia, Alberta and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. “Xenon,” the Xenon logo, and “Extreme Genetics” are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
VP, Corporate Affairs & Investor Relations
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: [email protected]

Read more...
Xenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update

BURNABY, British Columbia, March 08, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the year ended December 31, 2016, and provided a corporate update for 2017.
Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, said, “Our continued progress in 2016 to advance our proprietary pipeline and partnerships has led us to this important inflection point for our company. Over the next few quarters, we expect to reach a number of key milestone events. The most imminent event is the topline data read-out from our XEN801 Phase 2 clinical trial in patients with moderate to severe acne, which is expected later this month. We also look forward to the topline data from the Phase 2 clinical trial of TV-45070 in post-herpetic neuralgia being conducted by Teva expected by mid-year. In addition, we anticipate Genentech advancing GDC-0310 into a Phase 2 clinical trial later this year, as well as our filing of an IND, or IND equivalent, in the fourth quarter for XEN901, a selective inhibitor of Nav1.6 for the treatment of epilepsy disorders.” Achievements and Anticipated Milestones Proprietary Pipeline XEN801 is a topical stearoyl Co-A desaturase-1, or SCD1 inhibitor, being developed for the treatment of moderate to severe acne. By targeting a reduction in the size and number of sebaceous glands, thereby reducing sebum production, Xenon believes XEN801 is a promising, novel treatment for acne, which could be better tolerated and without the serious side effects that often limit the use of currently approved retinoid treatments.

Enrollment of 165 subjects is now complete in the XEN801 Phase 2 clinical trial, which is a randomized, double-blind, multi-center, vehicle-controlled, parallel-group study designed to evaluate the efficacy, safety, tolerability and systemic exposure of XEN801 for the treatment of moderate to severe facial acne. Patients apply a gel formulation of XEN801 (or vehicle placebo) topically to their face once daily in the evening for 12 weeks with a 4-week follow up. The primary efficacy endpoint is the percent change in total (inflammatory and non-inflammatory) lesion count from baseline to week 12. Secondary endpoints include separate efficacy assessments of inflammatory lesion counts, non-inflammatory lesion counts, and Investigator's Global Assessment (IGA) measures. Topline results from the XEN801 Phase 2 clinical trial are expected in the latter part of March.

XEN901 is a potent, selective Nav1.6 inhibitor for the treatment of rare infantile epileptic encephalopathies and other forms of epilepsy. XEN901 has demonstrated efficacy against seizures in an animal model of Nav1.6 gain-of-function SCN8A epilepsy as well as models that support the treatment of adult partial onset epilepsy. Xenon expects to file an investigational new drug (IND), or IND equivalent, application in the fourth quarter of 2017. Partnered Programs
TV-45070 is a topical sodium channel inhibitor being developed in collaboration with Xenon’s partner, Teva Pharmaceutical Industries Ltd., for the treatment of neuropathic pain. Teva is currently conducting a randomized, double-blind, placebo-controlled Phase 2b clinical trial of TV-45070 in patients with post-herpetic neuralgia, with topline results expected in mid-2017.

Xenon's collaborator Genentech, a member of the Roche Group, has completed two Phase 1 clinical trials for GDC-0276 and GDC-0310, which are both oral, selective Nav1.7 small-molecule inhibitors. Genentech has indicated that it intends to focus its ongoing development efforts on GDC-0310. Pending a full assessment of the Phase 1 clinical results and ongoing in vivo studies, Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain. 2016 Financial Results Cash and cash equivalents and marketable securities as of December 31, 2016 were $64.1 million, compared to $58.7 million as of December 31, 2015. There were 17,930,590 common shares outstanding as of December 31, 2016. For the year ended December 31, 2016, Xenon reported total revenue of $1.8 million, compared to $15.6 million for the same period in 2015. Revenue in both periods was primarily derived from Xenon's collaboration agreements with Teva and Genentech. The decrease of $13.8 million was primarily attributable to revenue recognized related to the upfront payment from the collaborative development and license agreement with Teva which was fully recognized by December 2015, as well as revenue related to the upfront payment from the March 2014 genetics collaborative agreement with Genentech which was fully recognized by March 2016. The remaining decrease was due to less full time equivalent funding from Genentech as resources were shifted from supporting collaborations to Xenon’s proprietary programs. Research and development expenses for the year ended December 31, 2016 were $19.8 million, compared to $15.2 million for the same period in 2015. The increase of $4.7 million was primarily attributable to an increase in spending on the XEN901, Nav1.6 sodium channel inhibitor program, as well as XEN801 which entered Phase 2 clinical development in February 2016, partially offset by a decrease in Genentech collaboration expenses. General and administrative expenses for the year ended December 31, 2016 were $6.8 million, compared to $9.8 million in 2015. During 2015, a $1.7 million expense was recognized due to a fair value adjustment upon the reclassification of stock option awards granted to directors and certain consultants to liability classification. The remaining decrease is due to one-time severance cost resulting from an internal reorganization and acceleration of stock-based compensation expense for certain consultants that occurred in 2015. Other income for the year ended December 31, 2016 was $1.8 million, compared to other expense of $6.4 million for the same period in 2015. The change of $8.2 million was primarily driven by unrealized foreign exchange gains in 2016 arising from the translation of Canadian denominated balances to U.S. dollars as compared to unrealized foreign exchange losses for the same period in 2015. Net loss for the year ended December 31, 2016 was $23.0 million, compared to $15.8 million for the same period in 2015. The change was primarily attributable to lower revenue and higher research and development expenses, partially offset by lower general and administrative expenses and the change in unrealized foreign exchange gain (loss). Conference Call Information Xenon will host a conference call and live audio webcast today at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its 2016 financial results and to provide a business update. To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 78824693. The webcast will be broadcast live on the “Investors” section of Xenon's website at www.xenon-pharma.com and will be available for replay following the call for 30 days. About Xenon Pharmaceuticals Inc. Xenon is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that it intends to commercialize on its own and for larger market indications that the company intends to partner with global pharmaceutical companies. Xenon has built a core enabling discovery platform, referred to as Extreme Genetics, for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Xenon's Extreme Genetics platform has yielded the first approved gene therapy product in the European Union and a broad development pipeline and multiple pharmaceutical partnerships, including with Teva and Genentech. For more information, please visit www.xenon-pharma.com. Safe Harbor Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding our ability to achieve milestones in both our proprietary and partnered development programs, the anticipated read out of topline results from the Phase 2 clinical trial of XEN801 and the Phase 2b clinical trial of TV-45070, the anticipated timing of IND submissions with regulatory agencies, the initiation of future clinical trials, the timing of and results from our and our collaborators’ ongoing clinical trials and pre-clinical development activities, the plans of our collaboration partners and their interactions with regulatory agencies, the potential efficacy, future development plans and commercial potential of our and our collaborators’ product candidates and the progress and potential of ongoing development programs. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical trials may not demonstrate safety and efficacy of any of our or our collaborators' product candidates; our Extreme Genetics discovery platform or ongoing collaborations may not yield additional product candidates; any of our or our collaborators' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones pursuant to our collaboration agreements; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission and the securities commissions in British Columbia, Alberta and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. “Xenon,” the Xenon logo, and “Extreme Genetics” are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.  XENON PHARMACEUTICALS INC.Condensed Consolidated Balance Sheets(Expressed in thousands of U.S. dollars)         December 31,  December 31,   2016  2015 Assets        Current assets:        Cash and cash equivalents and marketable securities $64,146  $58,651 Other current assets  1,529   2,215 Other assets  1,812   3,083 Total assets $67,487  $63,949          Liabilities        Current liabilities:        Accounts payable and accrued expenses  3,516   2,625 Deferred revenue  â€”   157 Non-current liabilities  70   133 Total liabilities $3,586  $2,915          Shareholders’ equity $63,901  $61,034 Total liabilities and shareholders’ equity $67,487  $63,949          
XENON PHARMACEUTICALS INC.Condensed Consolidated Statements of Operations(Expressed in thousands of U.S. dollars except share and per share amounts)      Year Ended December 31,   2016  2015  2014 Revenue:            Collaboration revenue $1,767  $15,573  $28,366 Royalties  36   4   4    1,803   15,577   28,370 Operating expenses:            Research and development  19,828   15,152   11,768 General and administrative  6,792   9,786   5,496 Total operating expenses  26,620   24,938   17,264 Income (loss) from operations  (24,817)  (9,361)  11,106 Other income (expense)  1,820   (6,391)  1,912 Net income (loss)  (22,997)  (15,752)  13,018              Net income (loss) per common share:            Basic $(1.48) $(1.10) $4.11 Diluted $(1.48) $(1.10) $3.28 Weighted-average common shares outstanding:            Basic  15,493,474   14,281,837   3,165,572 Diluted  15,493,474   14,281,837   3,963,797              

Investor/Media Contact:
Jodi Regts
Senior Director, Corporate Affairs
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: [email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.17
XENE's PB Ratio is ranked higher than
91% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. XENE: 1.17 )
Ranked among companies with meaningful PB Ratio only.
XENE' s PB Ratio Range Over the Past 10 Years
Min: 0.96  Med: 2.04 Max: 4.36
Current: 1.17
0.96
4.36
PS Ratio 65.00
XENE's PS Ratio is ranked lower than
78% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. XENE: 65.00 )
Ranked among companies with meaningful PS Ratio only.
XENE' s PS Ratio Range Over the Past 10 Years
Min: 5.22  Med: 9.05 Max: 110.26
Current: 65
5.22
110.26
EV-to-EBIT -0.25
XENE's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. XENE: -0.25 )
Ranked among companies with meaningful EV-to-EBIT only.
XENE' s EV-to-EBIT Range Over the Past 10 Years
Min: -11.4  Med: -2.5 Max: 50.2
Current: -0.25
-11.4
50.2
EV-to-EBITDA -0.25
XENE's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. XENE: -0.25 )
Ranked among companies with meaningful EV-to-EBITDA only.
XENE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.3  Med: -2.6 Max: 42
Current: -0.25
-13.3
42
EV-to-Revenue 8.20
XENE's EV-to-Revenue is ranked higher than
92% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. XENE: 8.20 )
Ranked among companies with meaningful EV-to-Revenue only.
XENE' s EV-to-Revenue Range Over the Past 10 Years
Min: -3.7  Med: 5.6 Max: 79.3
Current: 8.2
-3.7
79.3
Current Ratio 13.95
XENE's Current Ratio is ranked higher than
87% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. XENE: 13.95 )
Ranked among companies with meaningful Current Ratio only.
XENE' s Current Ratio Range Over the Past 10 Years
Min: 2.62  Med: 12.39 Max: 21.88
Current: 13.95
2.62
21.88
Quick Ratio 13.95
XENE's Quick Ratio is ranked higher than
87% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. XENE: 13.95 )
Ranked among companies with meaningful Quick Ratio only.
XENE' s Quick Ratio Range Over the Past 10 Years
Min: 2.62  Med: 12.39 Max: 21.88
Current: 13.95
2.62
21.88
Days Sales Outstanding 88.13
XENE's Days Sales Outstanding is ranked lower than
66% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. XENE: 88.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
XENE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.77  Med: 7.38 Max: 88.13
Current: 88.13
2.77
88.13

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -22.60
XENE's 3-Year Average Share Buyback Ratio is ranked lower than
66% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. XENE: -22.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
XENE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.6  Med: 0 Max: 0
Current: -22.6
-22.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.22
XENE's Price-to-Net-Cash is ranked higher than
95% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. XENE: 1.22 )
Ranked among companies with meaningful Price-to-Net-Cash only.
XENE' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.15  Med: 2.08 Max: 4.09
Current: 1.22
1.15
4.09
Price-to-Net-Current-Asset-Value 1.20
XENE's Price-to-Net-Current-Asset-Value is ranked higher than
96% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. XENE: 1.20 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
XENE' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.13  Med: 2 Max: 3.98
Current: 1.2
1.13
3.98
Price-to-Tangible-Book 1.16
XENE's Price-to-Tangible-Book is ranked higher than
93% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. XENE: 1.16 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
XENE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.09  Med: 1.9 Max: 3.85
Current: 1.16
1.09
3.85
Price-to-Median-PS-Value 7.22
XENE's Price-to-Median-PS-Value is ranked lower than
96% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. XENE: 7.22 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
XENE' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.69  Med: 0.93 Max: 7.78
Current: 7.22
0.69
7.78
Earnings Yield (Greenblatt) % -423.44
XENE's Earnings Yield (Greenblatt) % is ranked lower than
100% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. XENE: -423.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
XENE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5209.5  Med: -23.25 Max: 939.2
Current: -423.44
-5209.5
939.2

More Statistics

Revenue (TTM) (Mil) $0.82
EPS (TTM) $ -1.67
Short Percentage of Float1.07%
52-Week Range $2.25 - 9.95
Shares Outstanding (Mil)18.00

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}